Western Drug Makers Expand Use of India's Scientific Talent (India)
This article was originally published in PharmAsia News
India-based drug companies have been taking on pharmaceutical contracts from foreign partners for increasingly sophisticated research and drug discovery work, says Chemical & Engineering News head of the Asia-Pacific Bureau Jean-Francois Tremblay. Tremblay says this was particularly true beginning in 2005. India has a large pool of English-speaking scientists who are easy for global companies to work with. India also has a strong professional base of synthetic organic chemists who are highly motivated. (Click here for more
You may also be interested in...
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.
Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.